Onconetix, Inc. 8-K

What Happened Onconetix, Inc. announced that its board implemented a 1-for-5 reverse stock split of its common stock, effective 12:01 a.m. ET on March 25, 2026, following stockholder approval at a special meeting on February 3, 2026. The company filed the certificate of amendment with the Delaware Secretary of State on March 24, 2026; trading on The Nasdaq Capital Market continues under the symbol ONCO on a split‑adjusted basis and a new CUSIP 68237Q302 was assigned.

Key Details

• Reverse split ratio: 1-for-5 (board fixed this ratio on March 6, 2026; effective March 25, 2026).
• Outstanding shares reduced from 3,464,686 to 692,927. No change to authorized shares or par value ($0.00001).
• Fractional shares: no fractional shares issued; holders entitled to cash in lieu of fractions based on the adjusted closing sale price on March 24, 2026.
• Proportional adjustments were made to shares and exercise prices for equity awards, convertible preferred stock and warrants. Brokers automatically adjusted brokerage account positions; certificated shareholders may exchange certificates but are not required. Transfer agent: Continental Stock Transfer & Trust Company (212-509-4000).

Why It Matters A reverse stock split reduces the number of outstanding shares and can increase the per‑share price, which may affect per‑share metrics, Nasdaq listing appearance, and trading liquidity. The split does not change any stockholder’s percentage ownership except for rounding/cash‑out for fractional shares. Retail investors should verify updated share counts and CUSIP with their broker or the transfer agent and note adjusted option/convertible terms for any holdings.